Combining best of both worlds for cancer modeling

Combining best of both worlds for cancer modeling
The potential of bioengineered microscale organotypic models for precision medicine. Credit: Terry Juang

Despite cancer being a leading cause of death worldwide, treatment options for many types of cancers remain limited. This is partly due to the in vitro tools used to model cancers, which cannot adequately predict the behavior of a cancer or its sensitivity to drugs.

Further, animal models, like mice, biologically differ from humans in ways that play a critical role in immunotherapy, and results from animal studies do not always translate well to human disease.

These shortcomings point to a clear need for a better, patient-specific model to improve the understanding of cancer cells and their impacts.

Read:Beware pet ‘bearded dragons’: CDC says they could carry salmonella

Researchers from the University of Wisconsin and the University of California, San Francisco suggest bioengineered microscale organotypic models (BMOMs) can address this need. They discuss the advantages and capabilities of this technique, as well as its challenges, in the journal APL Bioengineering.

Due to their very small size, BMOMs require only a tiny patient-derived biopsy sample to monitor biological processes. This reduces any concern about the translatability of findings, since all the associated models are developed directly from human material. In addition, BMOMs can be integrated with microscopes and miniaturized sensors to watch the response of the cell culture to test treatments in high resolution and real time.

“BMOMs attempt to merge the best of in vivo and in vitro models,” said David Beebe, one of the authors. “These models place human cells in a more realistic environment context, where they are more likely to respond to treatment in a way more reflective of the patient response.

“The 3-D and multicellular attributes of BMOMs capture more of the myriad and complex cell-cell and cell-matrix interactions that regulate treatment response.”

Though promising, these devices have several limitations. They are difficult to fabricate in large quantities, and they require specialized training to use. Beyond these hurdles, BMOMs are also restricted in their capacity to consider human behavioral responses and fall short in modeling the interactions that occur between multiple organs in complex diseases.

Read:Acute respiratory failure mortality increases in United States and may worsen with COVID-19 pandemic

With additional research and clinical trials, the authors are optimistic about the applications of BMOMs. Their use with primary cells taken directly from patient tissue can help with patient-specific cancer treatments and drug testing.

Lab-grown tumor models could lead to improved ovarian cancer treatments

Read:China approves second domestic COVID-19 vaccine

More information:
Jose M. Ayuso et al, Toward improved in vitro models of human cancer, APL Bioengineering (2021). DOI: 10.1063/5.0026857

Provided by
American Institute of Physics

Combining best of both worlds for cancer modeling (2021, January 21)
retrieved 21 January 2021

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Source link

Previous post
Why we need detailed tumor profiling
Next post
Abnormal hyperactivation in the brain may be an early sign of Alzheimer’s